These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 23023107)
1. Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species. Jones RN; Flamm RK; Sader HS; Stilwell MG Diagn Microbiol Infect Dis; 2013 Jan; 75(1):89-93. PubMed ID: 23023107 [TBL] [Abstract][Full Text] [Related]
2. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). Pfaller MA; Flamm RK; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158 [TBL] [Abstract][Full Text] [Related]
3. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Morrissey I; Ge Y; Janes R Int J Antimicrob Agents; 2009 Jun; 33(6):515-9. PubMed ID: 19203863 [TBL] [Abstract][Full Text] [Related]
4. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
6. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012). Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953 [TBL] [Abstract][Full Text] [Related]
10. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). Farrell DJ; Flamm RK; Jones RN; Sader HS Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404 [TBL] [Abstract][Full Text] [Related]
11. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Pfaller MA; Farrell DJ; Sader HS; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. Pillar CM; Aranza MK; Shah D; Sahm DF J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006). Fritsche TR; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000 [TBL] [Abstract][Full Text] [Related]
14. Accuracy of the Thermo Fisher Scientific (Sensititre™) dry-form broth microdilution MIC product when testing ceftaroline. Jones RN; Holliday NM; Critchley IA Diagn Microbiol Infect Dis; 2015 Apr; 81(4):280-2. PubMed ID: 25623933 [TBL] [Abstract][Full Text] [Related]
15. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. Flamm RK; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2014 Apr; 78(4):437-42. PubMed ID: 24582578 [TBL] [Abstract][Full Text] [Related]
16. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. Sader HS; Flamm RK; Farrell DJ; Jones RN Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950 [TBL] [Abstract][Full Text] [Related]
17. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Jones ME Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Karlowsky JA; Adam HJ; Decorby MR; Lagacé-Wiens PR; Hoban DJ; Zhanel GG Antimicrob Agents Chemother; 2011 Jun; 55(6):2837-46. PubMed ID: 21402844 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456 [TBL] [Abstract][Full Text] [Related]
20. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Steed ME; Rybak MJ Pharmacotherapy; 2010 Apr; 30(4):375-89. PubMed ID: 20334458 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]